Navigation Links
BioMarin to Present at the Credit Suisse Healthcare Conference
Date:11/3/2011

NOVATO, Calif., Nov. 3, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development at BioMarin, will present a company update at the Credit Suisse Healthcare Conference in Phoenix on Thursday, November 10, 2011 at 3:30 p.m. MST.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA; PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU; BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/I
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMarin Announces Roll-Out of National PKU Registry
2. BioMarin to Present at the Citi Biotech Day
3. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
4. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
5. BioMarin Corrects Information Included in Bloomberg Article
6. BioMarin Announces Third Quarter 2008 Financial Results
7. BioMarin to Present at the Credit Suisse Healthcare Conference
8. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
9. BioMarin to Present at the Piper Jaffray Healthcare Conference
10. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
11. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... July 24, 2015 Orexigen Therapeutics, Inc. (Nasdaq: ... for the second quarter 2015 on Thursday, August 6 ... provide a business update and discuss the financial results ... a.m. Eastern Time (5:00 a.m. Pacific Time). ... calling (800) 447-0521 (domestic) or (847) 413-3238 (international), participant ...
(Date:7/23/2015)... July 23, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... results for the second quarter 2015 on Thursday, August 6, ... and webcast on that day at 5:00 pm ET to ... business update. The call will be hosted by Andrew ... , , , LIVE CALL: , , , ...
(Date:7/23/2015)... ... July 23, 2015 , ... July 23, ... providing more targeted treatment options with fewer side effects, according to Erik P. ... Cancer Center. , At the American Brain Tumor Association (ABTA) National Patient and ...
(Date:7/23/2015)... , July 23, 2015 /PRNewswire/ – Sigma-Aldrich Corporation ... high technology company, today announced the Company has received ... its Dekalb and ... Louis . The certification extends Sigma-Aldrich,s ability to ... proteins and antibodies used in diagnostic assays, and provides ...
Breaking Biology Technology:ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 2Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 2Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 3Sigma-Aldrich Meets Evolving Quality and Regulatory Needs with ISO 13485 Expansion, Provides Diagnostic Customers with Reliable Critical Raw Materials 2Sigma-Aldrich Meets Evolving Quality and Regulatory Needs with ISO 13485 Expansion, Provides Diagnostic Customers with Reliable Critical Raw Materials 3
... Signal Genetics, the parent company of Myeloma Health, ... oncology, today announced the formation of their Scientific Advisory ... Director, Jerome Lipper Multiple Myeloma Center, ... Medicine, Harvard Medical School Dr. Anderson of ...
... Calif., Oct. 26 Telik, Inc. (Nasdaq: ... company,s lead therapeutic product candidate, has been selected by ... Top 10 Most Interesting Oncology Projects to Watch."  Windhover ... executives in the pharmaceutical, biotechnology, and medical device industries. ...
... Regado Biosciences, a privately held company leading the development ... David J. Mazzo, PhD, President and CEO, will be ... Mazzo,s presentation will be given at the Waldorf-Astoria Hotel ... at 10:45 a.m. EDT in the Louis XVI Room. ...
Cached Biology Technology:Signal Genetics Announces Establishment of Scientific Advisory Board 2Signal Genetics Announces Establishment of Scientific Advisory Board 3TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch 2TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch 3Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City 2Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City 3
(Date:6/30/2015)... , June 30, 2015 To bolster its efforts ... HYPR Corp. announced today the addition of two new team ... as board advisor and David Raviv will act ... underscore HYPR Corp.,s commitment to providing the most secure solutions ... Sirota co-founded Layer 7 Technologies, a provider of security ...
(Date:6/25/2015)... , June 25, 2015  Imagine a tool specifically ... a healthier, happier life. That,s exactly what USANA,s ... do. The cutting-edge, portable health program provides a personalized ... to help improve your lifestyle and nutrition. ... and gala Wednesday night, USANA,s THA was honored with ...
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... Photosynthesis takes place in specialized membrane systems, made up ... A team of Ludwig-Maximilians-Universitaet (LMU) in Munich has now ... the edge of each stack. Scanning electron microscopy ... mays ) showing thylakoids (green) and assimilation starch granules ...
...  Polymer Technology Systems, Inc. (PTS, Inc.), the U.S.-based manufacturer ... products, has announced the issuance of two new U.S. ... of health data collected by point-of-care testing devices using ... a method and apparatus for manufacturing disposable dry test ...
... 2013 /PRNewswire-iReach/ -- Urologyweb.com, a leading website from Dr. ... outlining which prostate cancers really need treatment. ... favorable-risk Gleason 6 (3+3) prostate cancer and the ... not progress and do not need any treatment whether through ...
Cached Biology News:Photosynthesis: Membranes in tight corners 2PTS, Inc. Announces Two New Patents 2Which Prostate Cancers Really Need Treatment? 2Which Prostate Cancers Really Need Treatment? 3
Sphingosine 1-phosphate receptor Edg-1...
Bag-1 (K-20)...
... atoms at the 3, 3', 4, and ... as an internal standard for the quantification ... LC-mass spectrometry. PGE2 is one of the ... one of the most widely investigated prostaglandins. ...
, Glycerol 30%...
Biology Products: